{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T04:24:30Z","timestamp":1720585470990},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Medical Research Council Developmental Pathway Research Scheme","award":["G0802469"],"award-info":[{"award-number":["G0802469"]}]},{"name":"UCL Business","award":["11-055","12-020)"],"award-info":[{"award-number":["11-055","12-020)"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.vph.2014.12.002","type":"journal-article","created":{"date-parts":[[2014,12,24]],"date-time":"2014-12-24T04:49:44Z","timestamp":1419396584000},"page":"11-15","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Genetic therapies to lower cholesterol"],"prefix":"10.1016","volume":"64","author":[{"given":"Bernard","family":"Khoo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.vph.2014.12.002_bb0005","doi-asserted-by":"crossref","first-page":"9214","DOI":"10.1074\/jbc.M008890200","article-title":"The molecular mechanism for the genetic disorder familial defective apolipoprotein B100","volume":"276","author":"Boren","year":"2001","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.vph.2014.12.002_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(02)00330-1","article-title":"A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia","volume":"168","author":"Marks","year":"2003","journal-title":"Atherosclerosis"},{"issue":"32","key":"10.1016\/j.vph.2014.12.002_bb0015","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"issue":"20","key":"10.1016\/j.vph.2014.12.002_bb0020","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.vph.2014.12.002_bb0025","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJM199805283382203","article-title":"Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease","volume":"338","author":"Tybjaerg-Hansen","year":"1998","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vph.2014.12.002_bb0030","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.atherosclerosis.2007.06.028","article-title":"A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia","volume":"197","author":"Marais","year":"2008","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.vph.2014.12.002_bb0035","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.atherosclerosis.2008.02.009","article-title":"Recommendations for the use of LDL apheresis","volume":"198","author":"Thompson","year":"2008","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.vph.2014.12.002_bb0040","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1172\/JCI116663","article-title":"Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery","volume":"92","author":"Ishibashi","year":"1993","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.vph.2014.12.002_bb0045","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/nm1195-1148","article-title":"A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia","volume":"1","author":"Grossman","year":"1995","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.vph.2014.12.002_bb0050","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/hum.2012.108","article-title":"Adeno-associated virus serotype 8 gene therapy leads to significant lowering of plasma cholesterol levels in humanized mouse models of homozygous and heterozygous familial hypercholesterolemia","volume":"24","author":"Kassim","year":"2013","journal-title":"Hum Gene Ther"},{"issue":"5","key":"10.1016\/j.vph.2014.12.002_bb0055","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1194\/jlr.M400492-JLR200","article-title":"An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis","volume":"46","author":"Crooke","year":"2005","journal-title":"J Lipid Res"},{"issue":"16","key":"10.1016\/j.vph.2014.12.002_bb0060","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.105.606442","article-title":"Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B","volume":"114","author":"Kastelein","year":"2006","journal-title":"Circulation"},{"issue":"9719","key":"10.1016\/j.vph.2014.12.002_bb0065","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vph.2014.12.002_bb0070","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1194\/jlr.M011791","article-title":"Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice","volume":"52","author":"Mullick","year":"2011","journal-title":"J Lipid Res"},{"key":"10.1016\/j.vph.2014.12.002_bb0075","author":"Federal Drug Administration"},{"key":"10.1016\/j.vph.2014.12.002_bb0080","author":"European Medicines Agency"},{"issue":"7089","key":"10.1016\/j.vph.2014.12.002_bb0085","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nature04688","article-title":"RNAi-mediated gene silencing in non-human primates","volume":"441","author":"Zimmermann","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.vph.2014.12.002_bb0090","series-title":"Tekmira Pharmaceuticals Completes ApoB SNALP Phase 1 Clinical Trial [press release]","year":"2010"},{"issue":"12","key":"10.1016\/j.vph.2014.12.002_bb0095","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","article-title":"The PCSK9 decade","volume":"53","author":"Lambert","year":"2012","journal-title":"J Lipid Res"},{"issue":"9836","key":"10.1016\/j.vph.2014.12.002_bb0100","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"Stein","year":"2012","journal-title":"Lancet"},{"issue":"9911","key":"10.1016\/j.vph.2014.12.002_bb0105","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","article-title":"Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial","volume":"383","author":"Fitzgerald","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vph.2014.12.002_bb0110","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1161\/CIRCRESAHA.115.304351","article-title":"Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing","volume":"115","author":"Ding","year":"2014","journal-title":"Circ Res"},{"issue":"19","key":"10.1016\/j.vph.2014.12.002_bb0115","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","article-title":"Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia","volume":"128","author":"Stein","year":"2013","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.vph.2014.12.002_bb0120","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1194\/jlr.R300002-JLR200","article-title":"Familial hypobetalipoproteinemia: a review","volume":"44","author":"Schonfeld","year":"2003","journal-title":"J Lipid Res"},{"key":"10.1016\/j.vph.2014.12.002_bb0125","first-page":"184","article-title":"Familial hypobeta-lipoproteinemia: studies in 13 kindreds","volume":"90","author":"Glueck","year":"1977","journal-title":"Trans Assoc Am Physicians"},{"key":"10.1016\/j.vph.2014.12.002_bb0130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2199-8-3","article-title":"Antisense oligonucleotide-induced alternative splicing of the APOB mRNA generates a novel isoform of APOB","volume":"8","author":"Khoo","year":"2007","journal-title":"BMC Mol Biol"},{"issue":"1\u20132","key":"10.1016\/j.vph.2014.12.002_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-4781(00)00219-0","article-title":"RNA editing: cytidine to uridine conversion in apolipoprotein B mRNA","volume":"1494","author":"Chester","year":"2000","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"10.1016\/j.vph.2014.12.002_bb0140","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/mt.2012.264","article-title":"Exon skipping of hepatic APOB pre-mRNA with splice-switching oligonucleotides reduces LDL cholesterol in vivo","volume":"21","author":"Disterer","year":"2013","journal-title":"Mol Ther"},{"issue":"9860","key":"10.1016\/j.vph.2014.12.002_bb0145","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.vph.2014.12.002_bb0150","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1007\/s00125-011-2157-x","article-title":"Hepatic steatosis does not cause insulin resistance in people with familial hypobetalipoproteinaemia","volume":"54","author":"Visser","year":"2011","journal-title":"Diabetologia"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189114002080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189114002080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T19:21:24Z","timestamp":1537989684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189114002080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":30,"alternative-id":["S1537189114002080"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2014.12.002","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic therapies to lower cholesterol","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2014.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}